Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.

@article{ChristCrain2006ProcalcitoninGO,
  title={Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.},
  author={Mirjam Christ-Crain and Daiana Stolz and Roland Bingisser and Christian E. M{\"u}ller and David Miedinger and Peter R Huber and Werner Zimmerli and Stephan Harbarth and Michael Tamm and Beat M{\"u}ller},
  journal={American journal of respiratory and critical care medicine},
  year={2006},
  volume={174 1},
  pages={
          84-93
        }
}
RATIONALE In patients with community-acquired pneumonia, guidelines recommend antibiotic treatment for 7 to 21 d. Procalcitonin is elevated in bacterial infections, and its dynamics have prognostic implications. OBJECTIVE To assess procalcitonin guidance for the initiation and duration of antibiotic therapy in community-acquired pneumonia. METHODS In a randomized intervention trial, 302 consecutive patients with suspected community-acquired pneumonia were included. Data were assessed at… 

Figures and Tables from this paper

Procalcitonin for guidance of antibiotic therapy

TLDR
This review aims to provide physicians with an overview of the strengths and limitations of procalcitonin guidance for antibiotic therapy when used in different clinical settings and in patients with different underlying infections.

Procalcitonin-Guided Antibiotic Use in Acute Exacerbations of Idiopathic Pulmonary Fibrosis

TLDR
Procalcitonin-guided antibiotic therapy of patients with acute exacerbation of idiopathic pulmonary fibrosis may result in reduced exposure to antibiotics without adversely affecting patient outcomes.

Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis.

TLDR
Procalcitonin guidance can safely reduce antibiotic usage when used to discontinue antibiotic therapy in adult ICU patients and whenUsed to initiate or discontinue antibiotics in adult patients with respiratory tract infections.

Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study

TLDR
Serum procalcitonin reduces antibiotic therapy exposure in patients with ventilator associated pneumonia and significantly increased the number of antibiotic free-days alive 28 days after VAP onset.

Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial

TLDR
The serum PCT concentration can be used to effectively determine whether the acute asthma patients have bacterial infections in the respiratory tract, and to guide the use of antibiotics in the treatment of acute asthma exacerbations, which may substantially reduce unnecessary antibiotic use without compromising the therapeutic outcomes.

Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection

TLDR
A simple one-point PCT measurement for guiding decisions on antibiotic treatment is non-inferior to standard treatment in terms of safety, and effectively reduced the antibiotic treatment rate by 41.6%.

Procalcitonin as a Guide of Antibiotics Administration in Lower Respiratory Tract Infection

TLDR
Procalcitonin-guided antibiotic treatment in patients with acute respiratory infections effectively reduced antibiotic exposure and antibiotic side-effects while reducing the length of hospitalization and treatment duration and accordingly, decrease the expenditure of patients’ treatment and avoid antibiotic resistance.

Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care.

TLDR
As an adjunct to guidelines, procalcitonin-guided therapy markedly reduces antibiotic use for acute respiratory tract infections in primary care without compromising patient outcome.

Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial

TLDR
Monitoring of PCT is a helpful tool for guiding antibiotic treatment in surgical intensive care patients and may contribute to an optimized antibiotic regimen with beneficial effects on microbial resistance and costs in intensive care medicine.
...

References

SHOWING 1-10 OF 63 REFERENCES

Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia.

TLDR
Serum procalcitonin levels decreased during the clinical course of VAP but were significantly higher from Day 1 to Day 7 in patients with unfavorable outcomes, suggesting procalCitonin could be a prognostic marker of outcome during VAP.

Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners [ISRCTN73182671]

TLDR
The aim of this trial is to compare a ProCT-guided antibiotic therapy with a standard approach based on evidence-based guidelines for patients with ARTI in primary care with an open intervention.

Procalcitonin in bacterial infections--hype, hope, more or less?

TLDR
This review aims to help the clinician to understand the physiopathological basis, to appreciate strengths and weaknesses of this biomarker, and thereby to promote a rational implementation of ProCT in a routine setting.

Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial.

TLDR
Short-course, high-dose outpatient antibiotic therapy appears promising as an intervention to minimize the impact of antibiotic use on the spread of drug-resistant pneumococci.

Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.

  • T. File
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
TLDR
Available data suggest that with appropriate antibiotic selection, based on appropriate spectrum, potency, and pharmacokinetic/pharmacodynamic profile, lower respiratory tract infections in outpatients can be successfully treated in <7 days rather than the 7-14 days currently recommended.

Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome.

TLDR
Adherence to guidelines mainly depends on the hospital and the specialty and training status of prescribing physicians, and is an independent risk factor for treatment failure and mortality.

Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis.

TLDR
Patients with probable aspiration, previous hospitalization or antimicrobial treatment, and pulmonary comorbidity are especially prone to gram-negative bacteria, including Pseudomonas aeruginosa, which is also an independent risk factor for death in patients with CAP.

High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.

  • L. DunbarR. Wunderink J. Kahn
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2003
TLDR
It is demonstrated that 750 mg of levofloxacin per day for 5 days is at least as effective as 500 mg perday for 10 days for treatment of mild-to-severe CAP.
...